Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases

Abstract Background Fibrosing, non-idiopathic pulmonary fibrosis (non-IPF) interstitial lung diseases (fILDs) are a heterogeneous group of diseases characterized by a different amount of inflammation and fibrosis. Therapy is currently based on corticosteroids and/or immunomodulators. However, respon...

Full description

Bibliographic Details
Main Authors: Sebastiano Emanuele Torrisi, Nicolas Kahn, Julia Wälscher, Nilab Sarmand, Markus Polke, Kehler Lars, Monika Eichinger, Claus Peter Heussel, Stefano Palmucci, Francesca Maria Sambataro, Gianluca Sambataro, Domenico Sambataro, Carlo Vancheri, Michael Kreuter
Format: Article
Language:English
Published: BMC 2019-11-01
Series:BMC Pulmonary Medicine
Subjects:
Interstitial lung disease
Nintedanib
Pirfenidone
Progressive fibrosing interstitial lung diseases
Real-world experience
IPAF
Online Access:http://link.springer.com/article/10.1186/s12890-019-0937-0

Internet

http://link.springer.com/article/10.1186/s12890-019-0937-0

Similar Items